Milestone Pharmaceuticals Inc.
$2.04
▲
5.34%
2026-04-21 08:09:02
www.milestonepharma.com
NMS: MIST
Explore Milestone Pharmaceuticals Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$247.1 M
Current Price
$2.04
52W High / Low
$3.06 / $0.77
Stock P/E
—
Book Value
$0.34
Dividend Yield
—
ROCE
-62.4%
ROE
-2.3%
Face Value
—
EPS
$-0.75
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
38
Beta
0.69
Debt / Equity
139.76
Current Ratio
8.01
Quick Ratio
7.96
Forward P/E
-2.36
Price / Sales
153.74
Enterprise Value
$-14.43 M
EV / EBITDA
0.23
EV / Revenue
-9.33
Rating
Buy
Target Price
$6.6
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Kyntra Bio, Inc. | $7.34 | 0.16 | $29.62 M | — | -50.18% | -143.52% | $12.6 / $4.85 | $-7.42 |
| 2. | IO Biotech, Inc. | $0.01 | — | $0.55 M | — | -197.41% | -2.4% | $2.79 / $0.01 | $0.01 |
| 3. | BridgeBio Oncology Therapeutics, Inc. | $9.26 | 158.62 | $748.31 M | — | -35.28% | -48.23% | $14.87 / $8.08 | $5.14 |
| 4. | Sol-Gel Technologies Ltd. | $70 | — | $228.83 M | — | -31.74% | -23.72% | $97.97 / $4.11 | $8.19 |
| 5. | Precision BioSciences, Inc. | $7.58 | — | $187.43 M | — | -35.84% | -62.71% | $8.82 / $3.53 | $3.83 |
| 6. | Atara Biotherapeutics, Inc. | $4.99 | 1.29 | $42.24 M | — | 674.99% | -48.15% | $19.14 / $3.92 | $-5.26 |
| 7. | Coya Therapeutics, Inc. | $4.99 | — | $112.13 M | — | -51.17% | -51.39% | $7.75 / $3.71 | $2.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.55 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -17.26 M | -11.83 M | -12.53 M | -20.52 M | -12.35 M | — |
| Net Profit | -17.41 M | -11.92 M | -12.97 M | -20.76 M | -12.36 M | — |
| EPS in Rs | -0.15 | -0.1 | -0.11 | -0.18 | -0.11 | -0.14 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.55 M | 0 M | 1 M | 5 M |
| Operating Profit | -62.14 M | -42.1 M | -61.1 M | -59.64 M |
| Net Profit | -63.06 M | -41.52 M | -59.69 M | -58.39 M |
| EPS in Rs | -0.54 | -0.35 | -0.51 | -0.5 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 113.56 M | 75.5 M | 75.23 M | 74.48 M |
| Total Liabilities | 71.79 M | 62.35 M | 58.45 M | 8.13 M |
| Equity | 41.77 M | 13.15 M | 16.77 M | 66.35 M |
| Current Assets | 111.92 M | 73.93 M | 73.03 M | 71.8 M |
| Current Liabilities | 13.98 M | 8.13 M | 7.23 M | 6.14 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -49.04 M | -28.85 M | -46.42 M | -52.47 M |
| Investing CF | 11.25 M | 8.28 M | 4.76 M | -57.12 M |
| Financing CF | 85.53 M | 32.12 M | 47.79 M | 3.09 M |
| Free CF | -49.34 M | -28.88 M | -46.54 M | -52.74 M |
| Capex | -0.3 M | -0.03 M | -0.11 M | -0.27 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -80% | — | — |
| Earnings Growth % | 30.44% | -2.22% | — | — |
| Profit Margin % | — | -5968.5% | -1167.76% | — |
| Operating Margin % | — | -6109.8% | -1192.84% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -5703.9% | -1165.98% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.